Provided by Tiger Trade Technology Pte. Ltd.

Shuttle Pharmaceuticals Inc

1.63
+0.06003.82%
Post-market: 1.60-0.0289-1.77%19:59 EST
Volume:582.09K
Turnover:997.06K
Market Cap:4.37M
PE:-0.15
High:1.65
Open:1.56
Low:1.51
Close:1.57
52wk High:19.75
52wk Low:1.26
Shares:2.68M
Float Shares:2.55M
Volume Ratio:3.12
T/O Rate:22.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.1597
EPS(LYR):-79.6550
ROE:-27176.19%
ROA:-323.31%
PB:3.14
PE(LYR):-0.02

Loading ...

Company Profile

Company Name:
Shuttle Pharmaceuticals Inc
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
9
Office Location:
401 Professional Drive,Suite 260,Gaithersburg,Maryland,United States
Zip Code:
20879
Fax:
- -
Introduction:
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.

Directors

Name
Position
Anatoly Dritschilo
Chairman of the board and Chief Executive Officer
Adam Chambers
Director
Angel Liriano
Director
George Scorsis
Director
Oleh Nabyt
Director

Shareholders

Name
Position
Anatoly Dritschilo
Chairman of the board and Chief Executive Officer
Christopher R. Cooper
Interim Chief Executive Officer
Yuying Liang
Chief Financial Officer
Mira Jung
Chief Scientific Officer
Tyvin Rich
Chief Clinical Officer